A landmark in drug discovery based on complex natural product synthesis.
Satoshi KawanoKen ItoKenzo YahataKazunobu KiraTakanori AbeTsuyoshi AkagiMakoto AsanoKentaro IsoYuki SatoFumiyoshi MatsuuraIsao OhashiYasunobu MatsumotoMinetaka IsomuraTakeo SasakiTakashi FukuyamaYusuke MiyashitaYosuke KaburagiAkira YokoiOsamu AsanoTakashi OwaYoshito KishiPublished in: Scientific reports (2019)
Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce α-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products.